What's Going On With Capricor Therapeutics Stock Friday?
What's Going On With Capricor Therapeutics Stock Friday?
The trial also demonstrated increased skeletal function, particularly increased performance of upper limb.Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are trading higher on Friday. The company announced the long-term benefits of deramiocel for the treatment of duchenne muscular dystrophy (DMD).
Capricor Therapeutics公司（纳斯达克:CAPR）的股票周五交易上涨。该公司宣布使用deramiocel治疗杜氏肌萎缩症（DMD）具有长期益处。
What Happened: The biotechnology company said deramiocel increased cardiac function based on several different measures.
发生了什么: 这家生物技术公司表示，根据多种不同的措施，deramiocel提高了心脏功能。
The study found improvements in left ventricular ejection fraction, left ventricular end systolic volume and left ventricular end diastolic volume. Capricor stated that these measures are considered highly applicable when projecting future outcomes.
该研究发现，左心室射血分数、左心室收缩末期容积和左心室舒张末期容积均有所改善。Capricor表示，这些措施在预测未来结果时被认为是高度适用的。
The trial also demonstrated increased skeletal function, particularly increased performance of upper limb.
试验还表明了骨骼功能的增强，特别是上肢的性能提高。
The company based these positive findings off the ongoing HOPE-2 open label extension study. Capricor is expected to present these results at the Parent Project Muscular Dystrophy (PPMD) Annual Conference on Saturday.
该公司基于正在进行的HOPE-2开放标签延长研究得出了这些积极的发现。预计Capricor将在周六的Parent Project Muscular Dystrophy (PPMD)年度会议上展示这些结果。
Related Link: Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
相关链接: 华尔街上最准确的分析师们对3只具有3%以上股息收益率的医疗保健股票发表了看法
CAPR Price Action: Capricor Therapeutics shares are trading 4.39% higher at $4.84 at the time of writing per data from Benzinga Pro.
CAPR股价行动：根据Benzinga Pro的数据，Capricor Therapeutics股票在撰写本文时交易上涨4.39%，报4.84美元。
Image: Shutterstock/ REDPIXEL.PL
图片来源: shutterstock/REDPIXEL.PL